About Psilocybin & Psilocin

Psilocybin is a non-habit forming, naturally occurring psychedelic compound produced by more than 200 species of mushrooms. Once consumed is rapidly metabolized into Psilocin, which then acts on serotonin to produce the psychedelic effect.  



Our Products


We have developed six unique formulations to date in the form of Capsules (PSY-0.1),  Sublingual Spray (PSY-0.2), Gel Cap (PSY-0.3), Effervesce Tablets (PSY-0.4/0.5), Breath Strip (PSY-0.6). The precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually FDA approval in the treatment of Depression, Anxiety, Bi-polar disorder, Bulimia & Anorexia Nervosa, etc.  Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption. 

Market Opportunity (MEDICAL)

Mental Health (Depression, PTSD & Anxiety)

  • 450,000,000 people globally suffer from mental health illness

Eating Disorders (Anorexia, Bulimia & other classified EDs)

  • 70,000,000 people globally suffer from an eating disorder

Addiction (Alcohol, Drugs, Cigarettes)

  • 240,000,000 people globally suffer from addiction 

Market Opportunity (NUTRACEUTICAL)

Supplements for Brain Health & Cognitive Enhancement

  • Millions of people around the world are taking some form of   supplement (B12, B9, Omega 3, Vitamin D, Gingko Biloba and   others (4)) for brain health and/or cognitive enhancement   reasons

Global Market

  •  Global market size for these types of brain enhancing   supplements can reach $5.8 Billion US by 2023 (5)

Product Pipline  

  • One reason for selecting the sublingual route is to avoid drug destruction. Because gastric acid and intestinal and hepatic enzymes are bypassed, sublingual absorption can be more efficient overall for certain drugs than intestinal uptake. The onset of drug effect may also be quicker than with oral ingestion.
  • The sublingual route bypasses the first-pass metabolism and hencefacilitates rapid absorption of the drug into the systemic circulation. Drug directly reaches the systemic circulation using blood vessels
  • Administration through direct absorption into the mouth provides an advantage to medications you swallow. Sublingual drugs go into effect more quickly because they don’t have to go through your stomach and digestive system before being absorbed into the bloodstream


We have developed six unique formulations to date
  • Capsules
  • Sublingual Spray
  • Gel Cap
  • Effervesce Tablets
  • Breath Strip

Recently Acquired From Pharmather

Psilocybin in the Treatment of Neurological Brain Injury

United States Provisional Application

Serial No. 63/011,493 

Relates to pharmaceutical compositions comprising psilocybin and their use for the treatment of neurological brain injuries and migraines.

Psilocybin in the Treatment of Cancer

United States Provisional Application

Serial No. 63/113,913 

Psilocybin’s use of significant unmet medical needs for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.

Psilocybin Pharmaceutical Combination Therapies

United States Provisional Application

Serial No. 63/125,106 

Novel combinations of certain FDA approved drugs with psilocybin as a potential therapeutic option to reduce the side effects and improve the effectiveness of psilocybin to treat neurological disorders.

“With this acquisition, we have solidified our foundation in having a leading psychedelics pharmaceutical platform with a focus on proprietary psilocybin-based therapeutics that includes the development of an oral thin film product in collaboration with the University of Wisconsin-Madison, a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams, Professor and Researcher at North Carolina State University, a clinical study with the University of Wisconsin evaluating psilocybin in the treatment of methamphetamine use disorder, and PharmaTher’s psilocybin research initiatives and intellectual property in stroke, traumatic brain injury, cancer and drug combinations,” said Michael Frank, CEO of Revive. “We are now in a position to advance our psilocybin program for future clinical development in various unmet clinical needs in mental health, cancer and neurological disorders.”